Patents by Inventor Erwin W. Gelfand

Erwin W. Gelfand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200108119
    Abstract: Disclosed are methods to treat allergic conditions, including pulmonary and non-pulmonary conditions, in a subject by administering a composition that inhibits Pim kinase. Also disclosed are methods to treat allergic conditions in a subject by administering a composition that induces expression of Runx3.
    Type: Application
    Filed: June 26, 2019
    Publication date: April 9, 2020
    Inventors: Erwin W. Gelfand, Meiqin Wang
  • Patent number: 10369194
    Abstract: Disclosed are methods to treat allergic conditions, including pulmonary and non-pulmonary conditions, in a subject by administering a composition that inhibits Pim kinase. Also disclosed are methods to treat allergic conditions in a subject by administering a composition that induces expression of Runx3.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: August 6, 2019
    Assignee: National Jewish Health
    Inventors: Erwin W. Gelfand, Meiqin Wang
  • Publication number: 20190127740
    Abstract: The present invention relates to methods and compositions for treating and/or preventing allergic diseases or conditions by inhibiting one or more components of the steroidogenic pathway.
    Type: Application
    Filed: September 11, 2018
    Publication date: May 2, 2019
    Inventors: Erwin W. Gelfand, Meiqin Wang, Yi Jia
  • Patent number: 10100309
    Abstract: The present invention relates to methods and compositions for treating and/or preventing allergic diseases or conditions by inhibiting one or more components of the steroidogenic pathway.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: October 16, 2018
    Assignee: National Jewish Health
    Inventors: Erwin W. Gelfand, Meiqin Wang, Yi Jia
  • Publication number: 20180015143
    Abstract: Disclosed are methods to treat allergic conditions, including pulmonary and non-pulmonary conditions, in a subject by administering a composition that inhibits Pim kinase. Also disclosed are methods to treat allergic conditions in a subject by administering a composition that induces expression of Runx3.
    Type: Application
    Filed: July 31, 2017
    Publication date: January 18, 2018
    Inventors: Erwin W. Gelfand, Meiqin Wang
  • Publication number: 20170191063
    Abstract: The present invention relates to methods and compositions for treating and/or preventing allergic diseases or conditions by inhibiting one or more components of the steroidogenic pathway.
    Type: Application
    Filed: November 10, 2016
    Publication date: July 6, 2017
    Inventors: Erwin W. Gelfand, Meiqin Wang, Yi Jia
  • Patent number: 9534221
    Abstract: The present invention relates to methods and compositions for treating and/or preventing allergic diseases or conditions by inhibiting one or more components of the steroidogenic pathway.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: January 3, 2017
    Assignee: National Jewish Health
    Inventors: Erwin W. Gelfand, Meiqin Wang, Yi Jia
  • Publication number: 20140377310
    Abstract: Disclosed are methods to treat allergic conditions, including pulmonary and non-pulmonary conditions, in a subject by administering a composition that inhibits Pim kinase. Also disclosed are methods to treat allergic conditions in a subject by administering a composition that induces expression of Runx3.
    Type: Application
    Filed: June 30, 2014
    Publication date: December 25, 2014
    Inventors: Erwin W. Gelfand, Meiqin Wang
  • Patent number: 8802099
    Abstract: Disclosed are methods to treat allergic conditions, including pulmonary and non-pulmonary conditions, in a subject by administering a composition that inhibits Pim kinase. Also disclosed are methods to treat allergic conditions in a subject by administering a composition that induces expression of Runx3.
    Type: Grant
    Filed: November 10, 2011
    Date of Patent: August 12, 2014
    Assignee: National Jewish Health
    Inventors: Erwin W. Gelfand, Meiqin Wang
  • Publication number: 20140206749
    Abstract: The present invention relates to methods and compositions for treating and/or preventing allergic diseases or conditions by inhibiting one or more components of the steroidogenic pathway.
    Type: Application
    Filed: January 22, 2014
    Publication date: July 24, 2014
    Applicant: National Jewish Health
    Inventors: Erwin W. Gelfand, Meiqin Wang, Yi Jia
  • Publication number: 20140154307
    Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
    Type: Application
    Filed: February 18, 2014
    Publication date: June 5, 2014
    Applicants: MUSC Foundation for Research Development, National Jewish Health, The Regents of the University of Colorado, a body corporate
    Inventors: V. Michael HOLERS, Joshua M. Thurman, Christian Taube, Erwin W. Gelfand, Gary Steven Gilkeson
  • Patent number: 8703140
    Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
    Type: Grant
    Filed: August 22, 2007
    Date of Patent: April 22, 2014
    Assignees: MUSC Foundation for Research Development, National Jewish Health, The Regents of the University of Colorado, a body corporate
    Inventors: V. Michael Holers, Joshua M. Thurman, Christian Taube, Erwin W. Gelfand, Gary Gilkeson
  • Patent number: 8652475
    Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: February 18, 2014
    Assignees: MUSC Foundation for Research Development, National Jewish Health, The Regents of the University of Colorado, a body corporate
    Inventors: Vernon Michael Holers, Joshua M. Thurman, Christian Taube, Erwin W. Gelfand, Gary Steven Gilkeson
  • Publication number: 20120114663
    Abstract: Disclosed are methods to treat allergic conditions, including pulmonary and non-pulmonary conditions, in a subject by administering a composition that inhibits Pim kinase. Also disclosed are methods to treat allergic conditions in a subject by administering a composition that induces expression of Runx3.
    Type: Application
    Filed: November 10, 2011
    Publication date: May 10, 2012
    Applicant: NATIONAL JEWISH HEALTH
    Inventors: Erwin W. Gelfand, Meiqin Wang
  • Patent number: 7999082
    Abstract: Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and/or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.
    Type: Grant
    Filed: February 10, 2005
    Date of Patent: August 16, 2011
    Assignees: National Jewish Medical and Research Center, MUSC Foundation for Research Development, The Regents of the University of Coloraodo
    Inventors: Vernon Michael Holers, Joshua M. Thurman, Christian Taube, Erwin W. Gelfand, Gary Steven Gilkeson
  • Publication number: 20110002980
    Abstract: This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, an infectious disease, or a condition associated with a deleterious activity of a self-antigen. Also disclosed are therapeutic compositions useful in such a method.
    Type: Application
    Filed: April 8, 2010
    Publication date: January 6, 2011
    Applicant: NATIONAL JEWISH MEDICAL AND RESEARCH CENTER
    Inventors: STEVEN W. DOW, ROBYN E. ELMSLIE, JURGEN KARL JOHANNES SCHWARZE, ERWIN W. GELFAND
  • Publication number: 20100196376
    Abstract: Disclosed is a method to reduce airway hyperresponsiveness, such as allergen-induced airway hyperresponsiveness, in a mammal by administering an agent that increases the biological activity of a CGRP receptor. Also disclosed are methods for identifying compounds useful in the present method.
    Type: Application
    Filed: February 10, 2010
    Publication date: August 5, 2010
    Applicant: National Jewish Health
    Inventors: Erwin W. Gelfand, Azzeddine Dakhama
  • Patent number: 7741300
    Abstract: This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, an infectious disease, or a condition associated with a deleterious activity of a self-antigen. Also disclosed are therapeutic compositions useful in such a method.
    Type: Grant
    Filed: December 27, 2005
    Date of Patent: June 22, 2010
    Assignee: National Jewish Medical and Research Center
    Inventors: Steven W. Dow, Robyn E. Elmslie, Jurgen Karl Johannes Schwarze, Erwin W. Gelfand
  • Publication number: 20090162427
    Abstract: This invention relates to a vaccine and a method for immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic inflammation, an infectious disease, or a condition associated with a deleterious activity of a self-antigen. Also disclosed are therapeutic compositions useful in such a method.
    Type: Application
    Filed: March 6, 2009
    Publication date: June 25, 2009
    Applicant: NATIONAL JEWISH MEDICAL AND RESEARCH
    Inventors: Steven W. Dow, Robyn E. Elmslie, Jurgen Karl Johannes Schwarze, ERwin W. Gelfand
  • Patent number: 7160681
    Abstract: Disclosed are methods for assessing tumor cell growth in a patient for the diagnosis, monitoring and/or staging of tumor development. The method include the identification of reduced cdk6 expression or biological activity as an indicator of increased cell growth in a cell sample. The methods further include the identification of compounds which regulate cdk6 and the use of such compounds in a method for the regulation of inappropriate cell growth.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: January 9, 2007
    Assignee: National Jewish Medical and Research Center
    Inventors: Erwin W. Gelfand, Joseph J. Lucas